{"nctId":"NCT02251431","briefTitle":"Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome","startDateStruct":{"date":"2015-11","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus","Chronic Kidney Disease","Left Ventricular Diastolic Dysfunction"],"count":57,"armGroups":[{"label":"Exenatide-extended release","type":"EXPERIMENTAL","interventionNames":["Drug: BYDUREON"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"BYDUREON","otherNames":[]},{"name":"Placebo","otherNames":["Matching placebo subcutaneous injection"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18\n* Type 2 diabetes mellitus with hemoglobin A1C 6.6-9.9% with or without the use of insulin\n* Estimated glomerular filtration rate (eGFR) between 50 and 90 ml/min/1.73 m2\n\nExclusion Criteria:\n\n* Allergy or intolerance to gadolinium\n* Implanted cardiac pacemaker, defibrillator, loop recorder, or other implanted metallic device\n* Any other metallic implanted device that is a contra-indication to MRI scanning\n* eGFR \\< 50 ml/min/1.73 m2\n* eGFR \\> 90 ml/min/1.73 m2\n* Patient has ever been treated with an approved or investigational GLP-1 receptor agonist e.g. BYETTA™ (exenatide), BYDUREON™ (Exenatide extended-release), VICTOZA™ (liraglutide), or taspoglutide\n* Patient is enrolled in another experimental protocol which involves the use of an investigational drug or device, or an intervention that would interfere with the conduct of the trial.\n* Disorders of iron metabolism\n* Collagen vascular diseases\n* Myocardial infarction\n* Use of DDP4 inhibitors, and PPAR gamma agonists\n* Pregnancy or planned pregnancy during the trial period\n* Hemoglobin A1C of ≥ 10.0% or \\<6.6%\n* Fasting glucose ≥ 260 mg/dl\n* Clinically significant abnormal baseline laboratories\n* Morbid obesity or body girth that prohibits the ability to undergo echocardiography or MRI scanning with high-quality image results\n* Renal transplantation\n* Severe gastrointestinal, liver, or neurodegenerative disease\n* Decompensated liver cirrhosis (Child-Pugh score \\>7)\n* New York Heart Association Class III or IV heart failure\n* Patients have alanine aminotransaminase (ALT) greater than 5 times the upper limit of the reference range.\n* Prior pancreatitis\n* Personal or family history of medullary thyroid adenoma or carcinoma (MTC)\n* Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).\n* History of severe hypoglycemia\n* Prior bariatric surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Galectin-3","description":"Mean change in plasma galectin-3 (pg/ml)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9570.91","spread":"4990.06"},{"groupId":"OG001","value":"9266.7","spread":"6032.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9539.21","spread":"3893.04"},{"groupId":"OG001","value":"8098.78","spread":"6272.55"}]}]}]},{"type":"PRIMARY","title":"ST2","description":"Mean change in plasma ST2 (pg/ml)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"635.2","spread":"449.82"},{"groupId":"OG001","value":"443.18","spread":"380.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"524.68","spread":"423.61"},{"groupId":"OG001","value":"534.53","spread":"302.89"}]}]}]},{"type":"PRIMARY","title":"NGAL","description":"Mean change in urine neutrophil gelatinase associated lipocalin (NGAL):creatinine (Cr) ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.35","spread":"29.01"},{"groupId":"OG001","value":"18.44","spread":"25.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.01","spread":"14.87"},{"groupId":"OG001","value":"24.39","spread":"40.37"}]}]}]},{"type":"PRIMARY","title":"KIM-1","description":"Mean change in urine kidney injury molecule-1 (KIM-1):Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.08"},{"groupId":"OG001","value":"0.13","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.14"},{"groupId":"OG001","value":"0.1","spread":"0.05"}]}]}]},{"type":"PRIMARY","title":"L-FABP","description":"Mean change in urine L-type fatty acid binding protein:Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.61","spread":"3.72"},{"groupId":"OG001","value":"3.24","spread":"4.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"2.18"},{"groupId":"OG001","value":"3","spread":"2.85"}]}]}]},{"type":"PRIMARY","title":"IL-18","description":"Mean change in urine interleukin-18:Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"2.4"},{"groupId":"OG001","value":"3.48","spread":"4.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":"3.5"},{"groupId":"OG001","value":"2.68","spread":"2.48"}]}]}]},{"type":"PRIMARY","title":"Alpha GST","description":"Mean change in urine alpha glutathione S-transferase (αGST):Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.2"},{"groupId":"OG001","value":"0.67","spread":"1.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.16"},{"groupId":"OG001","value":"0.27","spread":"0.56"}]}]}]},{"type":"PRIMARY","title":"Troponin I","description":"Mean change in plasma ultrasensitive troponin I (pg/ml)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230.85","spread":"282.73"},{"groupId":"OG001","value":"415.65","spread":"446.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"238.53","spread":"283.59"},{"groupId":"OG001","value":"504.48","spread":"599.4"}]}]}]},{"type":"PRIMARY","title":"Pi GST","description":"Mean change in pi glutathione S-transferase (piGST):Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"3.41"},{"groupId":"OG001","value":"3.99","spread":"3.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"5.67"},{"groupId":"OG001","value":"4.27","spread":"4.67"}]}]}]},{"type":"PRIMARY","title":"NAG","description":"Mean change in urine N-acetyl-β-D-glucosaminidase (NAG):Cr ratio","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.35","spread":"29.01"},{"groupId":"OG001","value":"18.44","spread":"25.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.01","spread":"14.87"},{"groupId":"OG001","value":"24.39","spread":"40.37"}]}]}]},{"type":"PRIMARY","title":"Cystatin-C","description":"Mean paired change in urine cystatin-C:Cr ratio (uCysC:Cr)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.07","spread":"2.64"},{"groupId":"OG001","value":"1.84","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"1.22"},{"groupId":"OG001","value":"1.57","spread":"1.17"}]}]}]},{"type":"PRIMARY","title":"BNP","description":"Mean change in plasma B-type natriuretic peptide BNP (pg/ml)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.87","spread":"9.3"},{"groupId":"OG001","value":"9.88","spread":"14.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.59","spread":"9.59"},{"groupId":"OG001","value":"14.02","spread":"22.53"}]}]}]},{"type":"PRIMARY","title":"ACR","description":"Mean change in urine albumin:Cr ratio (ACR)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6678.23","spread":"12662.79"},{"groupId":"OG001","value":"9713.65","spread":"14380.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3963.49","spread":"3101.13"},{"groupId":"OG001","value":"9825.2","spread":"9539.34"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":["Gastrointestinal events, myalgia, fatigue","Injection site reaction"]}}}